Abstract: The invention relates to the purification, and cloning of receptors for the luteinizing hormone, choriogonadotropin, follicle stimulating hormone, and thyroid stimulating hormone. The invention additionally concerns the uses for such molecules in the diagnosis and therapy of human conditions.

Abstract: The invention relates to methods of treating injuries to or diseases of the central nervous system which methods involve increasing the active concentration(s) of transforming growth factor beta 1 (TGF-&bgr;1) and/or analogues thereof in the central nervous system of the patient. The present invention also provides pharmaceutical compositions comprising TGF-&bgr;1 and/or analogues thereof for administration to a patient prior to, simultaneous with, or following a neural insult, which compositions are useful in minimizing damage to the central nervous system that would otherwise occur following the insult.

Abstract: The invention relates to the purification, and cloning of receptors for the luteinizing hormone, choriogonadotropin, follicle stimulating hormone, and thyroid stimulating hormone. The invention additionally concerns the uses for such molecules in the diagnosis and therapy of human conditions.

Abstract: The invention relates to the purification, and cloning of receptors for the luteinizing hormone, choriogonadotropin, follicle stimulating hormone, and thyroid stimulating hormone. The invention additionally concerns the uses for such molecules in the diagnosis and therapy of human conditions.

Abstract: The invention relates to methods of treating injuries to or diseases of the central nervous system which methods involve increasing the active concentration(s) of transforming growth factor beta 1 (TGF-&bgr;1) and/or analogues thereof in the central nervous system of the patient. The present invention also provides pharmaceutical compositions comprising TGF-&bgr;1 and/or analogues thereof for administration to a patient prior to, simultaneous with, or following a neural insult, which compositions are useful in minimizing damage to the central nervous system that would otherwise occur following the insult.

Abstract: A method of treating injuries to or diseases of the central nervous system that predominantly affects glia and/or non-cholinergic neuronal cells characterized in that it comprises the step of increasing the active concentration(s) of insulin-like growth factor 1 and/or analogues thereof in the central nervous system of the patient. The present invention also provides therapeutic compositions comprising insulin-like growth factor 1 and/or analogues thereof for administration to a patient at or following a neural insult, which compositions are useful in minimizing damage to the central nervous system that would otherwise occur following the insult.

Abstract: A method of treating injuries to or diseases of the central nervous system that predominantly effects glia and/or non-cholinergic neuronal cells characterized in that it comprises the step of increasing the active concentration(s) of insulin-like growth factor 1 and/or analogues thereof in the central nervous system of the patient. The present invention also provides therapeutic compositions comprising insulin-like growth factor 1 and/or analogues thereof for administration to a patient at or following a neural insult, which compositions are useful in minimizing damage to the central nervous system that would otherwise occur following the insult.

Abstract: The invention relates to gonadoliberin derivatives of the general formula (I)Glp--His--Trp--Ser--Tyr--X.sub.1 --X.sub.2 --X.sub.3 --Pro--X.sub.4whereinX.sub.1 is a glycyl group or a D-isomer of any natural or synthetic amino acid group,X.sub.2 represents an L-amino acid group having 1 to 4 carbon atoms in the side chain, L-phenyl-alanyl or L-tryptophyl group,X.sub.3 represents an L-amino acid group having a C.sub.1-4 alkyl or C.sub.2-4 alkanoyl-amide side chain, andX.sub.4 is a glycine amide or a C.sub.1-4 alkyl amide group,with the proviso that if X.sub.1 stands for a group other than glycyl and X.sub.2 is a tryptophyl group then X.sub.3 may not be leucyl, and the addition salts formed with therapeutically useable acids and complexes thereof. Furthermore the invention relates to a process for preparing these compounds.The new gonadoliberin derivatives can be effectively used for the reproduction process of fish, birds and mammals.

Abstract: The invention relates to a process for obtaining ready-for-fertilization sexual products from sexually mature fish in a period independent of their natural spawning season, in which actual stage of ripening is determined by probing of sexual products [sperm or eggs], fish not yet ripe for ovulation are separated from ripe fish, compounds of hormonal effect are administered to fish, and after the ovulation sexual products are obtained from the fish or from their environment.In the process according to the invention a nonapeptide-C.sub.1-4 -alkyl-amide or a decapeptide amide of the general formula (I),Glp-His-Trp-Ser-Tyr-X.sub.1 -X.sub.2 -X.sub.3 -Pro-X.sub.4 (I)whereinX.sub.1 is a glycyl group or a D-isomer of any natural or synthetic amino acid group,X.sub.2 represents an L-amino acid group having 1 to 4 carbon atoms in the side chain, L-phenyl-alanyl or L-tryptophyl group,X.sub.3 represents an L-amino acid group having a C.sub.1-4 alkyl or C.sub.2-4 alkyl-amide side chain,X.sub.4 is a glycine-amide or a C.

Abstract: The invention relates to new gonadoliberin derivatives of the formula (I)Glp-His-Trp-Ser-Tyr-X-Leu-Arg-Pro-Y, (I)whereinY represents a glycine-amide group or an -NH-alkyl group having 1 to 4 carbon atoms in the alkyl moiety,X stands for a D-thyroxyl, D-thyronyl or D-4-chlorophenylalanyl group,and acid addition salts and metal complexes thereof.The new nona- and decapeptide derivatives have an excellent luteinizing and folliculus stimulating hormone releasing activity, and they can therefore be used as active ingredients in pharmaceutical compositions for human or veterinary application.